Study of CLR 125 for triple negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests an experimental drug called CLR 125 in people with triple negative breast cancer that has worsened after at least one prior treatment. It aims to see if the drug is safe and how it affects the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have triple negative breast cancer (ER and PR less than 10% each, HER2 negative).
- Your cancer has progressed after at least one prior standard treatment (such as chemotherapy, immunotherapy, or targeted therapy).
- You are 18 years or older.
- You are able to perform daily activities with minimal help (ECOG 0-2).
- You have adequate blood cell counts and organ function, as determined by lab tests.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (camrelizumab and pirfenidone) with chemotherapy to see if it can help people with advanced triple-negative breast cancer. It may offer a new treatment option for those whose cancer has progressed after initial treatment.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests a combination of two targeted medicines given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can improve outcomes for patients with this type of breast cancer.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial tests an experimental drug called QLC5513, either by itself or combined with another drug (QL1706), for people with triple-negative breast cancer that has continued to grow despite prior treatment. The goal is to see if this new approach can shrink tumors or slow the cancer's progression, and it might be an option if standard treatments have stopped working.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.